IGF-1 Identified as Possible Risk Factor For Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BOSTON--Investigators at McGill University, the Harvard School of Public Health, and Brigham and Women’s Hospital have identified insulinlike growth factor-1 (IGF-1) as a possible high-risk factor for prostate cancer.

BOSTON--Investigators at McGill University, the Harvard School of Public Health, and Brigham and Women’s Hospital have identified insulinlike growth factor-1 (IGF-1) as a possible high-risk factor for prostate cancer.

A comparison of blood samples from 152 men in the Physicians Health Study who developed prostate cancer and 152 controls who did not showed that the prostate cancer patients had higher

IGF-1 levels. The 25% of men with the highest IGF-1 levels were 4.3 times more likely to develop prostate cancer than the men with the lowest IGF-1 levels.

The blood samples were collected an average of 7 years prior to the men’s prostate cancer diagnosis, suggesting that, in most instances, the men did not have prostate cancer at the time the samples were drawn. This further suggests that high concentrations of IGF-1 may be a causative factor in the development of prostate cancer rather than just a marker of the presence of the disease.

The findings were published in the January 23, 1998, issue of the journal Science.

Recent Videos
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content